A forum for researchers, students and applicants in the field of cyclodextrin technology
OrganoTherapeutics in collaboration with University of Luxemburg has published interestingin vitro and in vivo results on the effects of HPBCD
During the webinar of CycloLab “Cyclodextrins as active ingredients in the 21st century” held on Oct. 11, 2021, the participants
Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111,
The use of CDs in nasal formulations allowed obtaining versatile drug delivery systems intended for local and systemic effects, as
The most common method to modify cellular cholesterol content in vitro is to incubate cells with cyclodextrin (CD). However, it
Inflammation is one of the usual biological responses to different pathologies or stimuli. As the incidence of inflammation related diseases
Cyclodextrin (CD) are classicaly know to be an excellent drug carrier although applications as active drug have been studied (orphan
Zhao et al. reported on a phase IIa, single-center, randomized, open-label, and dose-finding study that enrolled 35 patients under general
Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.
After the great success of the webinar held in May, 2021 a next webinar organized by CycloLab will be held
